A clinical trial to investigate the effectiveness of Sovodak for Hepatitis C in patients co-infected with HIV

Abstract

American college of gastroenterology guideline has suggested Sufosbuvir and Daclatasvir for treatment of hepatitis C in patients with concomitant hepatitis C and HIV. In 2016, Sovodak a combinition of Sofosbuvir & Daclatasvir was introduced. Previously the effectiveness of this drug in treatment of hepatitis C patients have been shown. However, there is no study that assess its effectiveness in hepatitis C patients co-infected with HIV. So, this study aimed at investigating the effectiveness of Sovodak for treatment of hepatitis C in patients co-infected with HIV. Method: At first, thirty four hepatitis C patients co-infected with HIV have been selected from behavioral disorders clinic. The patients’ blood sample have been sent for quantitative PCR and 7 patients were omitted from the study due to false positive results and one patient did not consent to participate in the study and 26 patients received Sovodak for 3 months. 12 weeks after the completion of the treatment the blood sample for qualitative PCR have been obtained and sustained virological response 12 weeks have been calculated. Results: Twenty six patients complete the study. The mean age of the paticipants was 44.92±7.22 years. Before treatment, the mean viral load was 4888463.96±4410227.75. About 73.1% of participants had virus genotype of 1a, 7.7% genotype 1b and 19.2% genotype 3a. After 3 months of intervention with sovodak, the SVR 12 was about 92.3%. In patients co-infected with virus genotype 1a, the SVR12 was 73.94% (18 patients out of 19), in patients with genotype 1b was 100% (2 patients) and in patients with genotype 3a was 80% (four out of five patients).